The Federal Hemp Shakeup

The Federal Hemp Shakeup: CMS’s 10‑Year Medicare Model Signals a Pharmaceutical Future for Cannabinoids

For years, the hemp industry has operated under the assumption that federal cannabinoid policy would remain fragmented, state‑driven, and commercially flexible. But a recent CMS communication reveals something far more consequential — a decade‑long federal plan that could fundamentally reshape hemp’s future.

The Centers for Medicare & Medicaid Services (CMS) has quietly extended its hemp‑derived cannabinoid initiative into a 10‑year Medicare model, signaling a long‑term federal shift toward pharmaceutical‑grade cannabinoid products. And the implications for hemp retailers, cannabis lenders, MMJ operators, and investors are profound.

This is not speculation. It is written plainly in CMS’s own documentation.

 

⭐ CMS’s Hemp Program Has a Physician Problem — And That’s the Point

CMS created the Substance Access Beneficiary Engagement Incentive (BEI), allowing certain Medicare organizations to furnish hemp‑derived cannabinoid products to seniors for symptom control.

But CMS also made physicians the final gatekeepers:

  • determining appropriateness

  • reviewing medications

  • assessing interactions

  • discussing risks

  • following the patient

This is explicitly stated in the CMS program description.

That means physicians — not CMS — decide whether hemp products are acceptable for medical use.

And physicians are already signaling their answer.

 

⭐ Physicians Want Pharmaceutical‑Grade Cannabinoids

Vantage Hemp’s Chief Medical Officer, Dr. Paul Shields, says healthcare requires:

  • standardized products

  • reproducible chemistry

  • controlled clinical trials

  • pharmacy dispensing

  • insurance reimbursement

This is not an anti‑cannabis voice. This is a cannabinoid manufacturer’s own medical officer explaining what healthcare requires for adoption.

He also questioned whether CMS’s pilot structure can generate credible medical evidence, noting that pharmaceutical companies rely on double‑blind clinical trials to establish concentration and efficacy.

In other words:

Physicians will not adopt hemp products unless they meet pharmaceutical standards.

 

⭐ CMS Is Extending Hemp Into a 10‑Year Medicare Model

Despite the unresolved scientific and clinical issues, CMS has already carried the BEI initiative into its new Long‑term Enhanced ACO Design (LEAD) model — a 10‑year Medicare framework running from 2027 through 2036.

CMS itself notes this is the longest performance period the Innovation Center has ever tested.

This raises a critical question:

Why institutionalize a hemp pathway for a decade before proving the products can generate the reproducible evidence physicians require?

The answer is in the next section.

 

⭐ The Executive Order: Cannabinoid Evidence Must Inform Standards of Care

Executive Order 14370 directs HHS, FDA, CMS, and NIH to develop research methods using real‑world evidence to improve access to hemp‑derived cannabinoid products “in accordance with Federal law and to inform standards of care.”

To inform standards of care, researchers must know:

  • what product patients received

  • its exact composition

  • its stability

  • its reproducibility

CMS cannot meet these requirements with unvalidated hemp products.

This is the federal pivot point.

 

⭐ The Government Cannot Have It Both Ways

CMS says:

  • the program is not Medicare drug coverage

  • FDA has not approved the hemp products as drugs

  • physicians must evaluate appropriateness, interactions, risks, and benefits

Meanwhile:

  • the Executive Order says evidence must inform standards of care

  • physicians say healthcare requires reproducible, standardized products

  • EFSA rejected Charlotte’s Web’s novel food application due to insufficient characterization and stability data

CMS is trying to run a medical program with non‑medical products.

And the email states the contradiction plainly:

“CMS can create an incentive, but it cannot create physician confidence in an unvalidated product.” — Duane Boise, MMJ CEO

 

⭐ MMJ Has Already Built the Pharmaceutical Pathway CMS Is Hinting At

MMJ spent:

  • eight years

  • more than $10 million

  • developing a defined soft‑gel capsule (5 mg CBD + 2.5 mg THC)

  • conducting chemical fingerprinting

  • performing stability work

  • establishing CMC controls

  • pursuing two FDA INDs

  • obtaining an Orphan Drug Designation

This is the pharmaceutical pathway.

And the CMS email makes it clear:

The medical community is asking for evidence, not marketing.

 

⭐ What This Means for Hemp Retailers, Cannabis Lenders, and MMJ Operators

1. Hemp retailers cannot meet CMS’s emerging standards.

Potency tests and COAs are not validation. CMS requires reproducible dosing, stability, and clinical evidence.

2. Cannabis lenders must prepare for a federal shift toward pharmaceutical cannabinoids.

The hemp retail model will not survive inside Medicare.

3. MMJ operators are not prepared either.

Most MMJ products lack:

  • reproducible chemistry

  • stability data

  • controlled trials

  • physician‑grade documentation

4. Pharmaceutical cannabinoid developers will dominate the federal medical market.

CMS is building a pathway that only FDA‑style cannabinoid drug developers can satisfy.

5. Industrial cannabinoid processors will be among the few survivors — and Galaxy Oil is a prime example.

As Medicare shifts toward pharmaceutical‑grade cannabinoid standards, retail hemp stores and boutique brands will not be able to meet the reproducibility, stability, and clinical documentation physicians require. But industrial manufacturers — companies capable of producing standardized oils and validated extracts at scale — are positioned to operate in the post‑retail cannabinoid economy.

Galaxy Oil represents exactly this class of companies. Even though Galaxy Oil does not publicly display an active processing facility today, their positioning matters: they are ingredient‑focused, manufacturing‑driven, and structurally aligned with the type of supply chain CMS’s 10‑year model will ultimately demand. Galaxy Oil is not a dispensary, not a boutique brand, and not a vape manufacturer — they are an industrial processor capable of supplying the reproducible cannabinoid inputs that pharmaceutical developers and Medicare‑aligned programs will require.

6. The hemp industry must prepare for federal medicalization.

This is not a crackdown. It is a sorting mechanism.

 

⭐ The Bottom Line

CMS is quietly constructing a decade‑long federal pathway that will push hemp‑derived cannabinoids into a pharmaceutical‑grade medical model. The agency is institutionalizing a program before proving the products meet the scientific standards physicians require — and that tension will reshape the entire hemp economy.

The hemp industry, cannabis lenders, MMJ operators, and policymakers must understand:

The future of hemp is not retail. The future of hemp is medicine. And medicine requires reproducible science.